Literature DB >> 12045715

Androgen and estrogen receptor mRNA status in apocrine carcinomas.

Gary L Bratthauer1, Ruth A Lininger, Yan-gao Man, Fattaneh A Tavassoli.   

Abstract

Eleven pure apocrine carcinomas (8 breast, 2 vulvar, 1 axillary) were evaluated for the presence of androgen and estrogen receptor mRNA. These immunohistochemically androgen receptor positive and estrogen receptor negative cases were microdissected and analyzed by the reverse transcription polymerase chain reaction for the presence of receptor message. Nine of these 11 estrogen receptor (ER) negative lesions were found to contain the ER mRNA through the first intron splice region. In 4 of the 11 cases, the androgen receptor (AR) mRNA could not be shown even though the protein was detected immunohistochemically. In the other seven, AR mRNA was identified. This indicates that the mechanism for production of the estrogen receptor is intact and functional in most cases through the first transcriptional splice region. Therefore, the immunohistochemical absence of the estrogen receptor in apocrine cells cannot be explained by an abnormal message at these common sites and should be sought beyond these points.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12045715     DOI: 10.1097/00019606-200206000-00008

Source DB:  PubMed          Journal:  Diagn Mol Pathol        ISSN: 1052-9551


  11 in total

1.  Update on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast carcinoma studies.

Authors:  Semir Vranic; Zoran Gatalica; Zhao-Yi Wang
Journal:  Oncol Lett       Date:  2011-11       Impact factor: 2.967

2.  ER-α36, a novel isoform of ER-α66, is commonly over-expressed in apocrine and adenoid cystic carcinomas of the breast.

Authors:  Semir Vranic; Zoran Gatalica; Hao Deng; Snjezana Frkovic-Grazio; Lisa M J Lee; Olga Gurjeva; Zhao-Yi Wang
Journal:  J Clin Pathol       Date:  2010-11-02       Impact factor: 3.411

Review 3.  Role of the androgen receptor in triple-negative breast cancer.

Authors:  Murtuza Rampurwala; Kari B Wisinski; Ruth O'Regan
Journal:  Clin Adv Hematol Oncol       Date:  2016-03

Review 4.  [Diagnostics of benign ductal epithelial cell proliferation of the breast in biopsy material].

Authors:  H-P Sinn; C Flechtenmacher; S Aulmann
Journal:  Pathologe       Date:  2014-02       Impact factor: 1.011

5.  Expression of estrogen receptor and estrogen receptor messenger RNA in gastric carcinoma tissues.

Authors:  Xin-Han Zhao; Shan-Zhi Gu; Shan-Xi Liu; Bo-Rong Pan
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

6.  Androgen Receptor Expression in Breast Carcinoma of Egyptian Patients.

Authors:  Rehab Monir Samaka; Sheren Fouad Younes
Journal:  J Clin Diagn Res       Date:  2016-11-01

Review 7.  Apocrine carcinoma of the breast: A brief update on the molecular features and targetable biomarkers.

Authors:  Semir Vranic; Rebecca Feldman; Zoran Gatalica
Journal:  Bosn J Basic Med Sci       Date:  2017-02-21       Impact factor: 3.363

8.  Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified?

Authors:  Damoun Safarpour; Shabnam Pakneshan; Fattaneh A Tavassoli
Journal:  Am J Cancer Res       Date:  2014-07-16       Impact factor: 6.166

9.  Androgen receptor expresion in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors.

Authors:  Luis O Gonzalez; Maria D Corte; Julio Vazquez; Sara Junquera; Rosario Sanchez; Ana C Alvarez; Juan C Rodriguez; Maria L Lamelas; Francisco J Vizoso
Journal:  BMC Cancer       Date:  2008-05-28       Impact factor: 4.430

Review 10.  Triple-negative breast cancer: new perspectives for targeted therapies.

Authors:  Federica Tomao; Anselmo Papa; Eleonora Zaccarelli; Luigi Rossi; Davide Caruso; Marina Minozzi; Patrizia Vici; Luigi Frati; Silverio Tomao
Journal:  Onco Targets Ther       Date:  2015-01-16       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.